TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
Carey K. Anders(Duke University), Lisa A. Carey(University of North Carolina at Chapel Hill), Antonio C. Wolff(Johns Hopkins University), Minetta C. Liu(Mayo Clinic), Jonathan S. Berg(University of North Carolina at Chapel Hill), Catherine Van Poznak(University of Michigan), Amal Melhem‐Bertrandt(The University of Texas MD Anderson Cancer Center), Nancy U. Lin(Dana-Farber Cancer Institute), Anna Maria Storniolo(Indiana University Health), Joel S. Parker(University of North Carolina at Chapel Hill), Vered Stearns(Johns Hopkins University), Charles M. Perou(University of North Carolina at Chapel Hill), P. Kelly Marcom(Duke University), Allison M. Deal(Memorial Sloan Kettering Cancer Center), Eric P. Winer(University of Vermont), Olga Karginova(University of Illinois Chicago), Amy H. Peterman(University of North Carolina at Charlotte), Vandana G. Abramson(Vanderbilt University), J. Keith Smith(Merck & Co., Inc., Rahway, NJ, USA (United States)), Aleix Prat(Hospital Clínic de Barcelona), John T. Carpenter(University of Louisville Hospital), Michelle Melisko(University of California, San Francisco), Shannon Puhalla(UPMC Hillman Cancer Center), Rita Nanda(University of Chicago)
Cited by 69
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k